State Street’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$186M Sell
12,893,897
-1,939,417
-13% -$27.8M 0.01% 978
2025
Q4
$211M Buy
14,833,314
+3,270,375
+28% +$32.1M 0.01% 907
2025
Q3
$91.1M Sell
11,562,939
-5,158
-0% -$36.7K ﹤0.01% 1380
2025
Q2
$66.3M Buy
11,568,097
+2,049,078
+22% +$13.2M ﹤0.01% 1532
2025
Q1
$77.7M Sell
9,519,019
-842,209
-8% -$7.79M ﹤0.01% 1402
2024
Q4
$97.6M Sell
10,361,228
-609,518
-6% -$6.34M ﹤0.01% 1349
2024
Q3
$117M Sell
10,970,746
-46,217
-0.4% -$503K ﹤0.01% 1236
2024
Q2
$109M Sell
11,016,963
-1,425,538
-11% -$14.6M ﹤0.01% 1202
2024
Q1
$147M Sell
12,442,501
-720,584
-5% -$9.22M 0.01% 1063
2023
Q4
$187M Buy
13,163,085
+1,790,649
+16% +$20.3M 0.01% 887
2023
Q3
$138M Buy
11,372,436
+193,194
+2% +$2.49M 0.01% 966
2023
Q2
$140M Buy
11,179,242
+48,357
+0.4% +$574K 0.01% 1004
2023
Q1
$123M Sell
11,130,885
-954,954
-8% -$11.8M 0.01% 1049
2022
Q4
$148M Buy
12,085,839
+63,627
+0.5% +$716K 0.01% 924
2022
Q3
$126M Sell
12,022,212
-1,896,103
-14% -$21.1M 0.01% 977
2022
Q2
$149M Buy
13,918,315
+1,983,752
+17% +$16.3M 0.01% 905
2022
Q1
$113M Buy
11,934,563
+1,432,498
+14% +$13.4M 0.01% 1208
2021
Q4
$121M Buy
10,502,065
+486,335
+5% +$5.42M 0.01% 1147
2021
Q3
$95.7M Buy
10,015,730
+579,481
+6% +$5.93M 0.01% 1300
2021
Q2
$91M Sell
9,436,249
-100,693
-1% -$983K ﹤0.01% 1368
2021
Q1
$94.2M Buy
9,536,942
+1,627,551
+21% +$25.2M 0.01% 1276
2020
Q4
$183M Sell
7,909,391
-1,019,668
-11% -$20.9M 0.01% 785
2020
Q3
$126M Sell
8,929,059
-1,354,448
-13% -$19.7M 0.01% 855
2020
Q2
$155M Sell
10,283,507
-845,644
-8% -$10.3M 0.01% 749
2020
Q1
$103M Buy
11,129,151
+132,427
+1% +$1.26M 0.01% 839
2019
Q4
$107M Sell
10,996,724
-584,457
-5% -$5.35M 0.01% 1000
2019
Q3
$92.9M Buy
11,581,181
+1,783,202
+18% +$19.4M 0.01% 1047
2019
Q2
$122M Buy
9,797,979
+1,134,496
+13% +$14.4M 0.01% 905
2019
Q1
$118M Buy
8,663,483
+108,931
+1% +$1.33M 0.01% 909
2018
Q4
$82M Sell
8,554,552
-936,561
-10% -$10.3M 0.01% 1026
2018
Q3
$115M Buy
9,491,113
+1,528,657
+19% +$21.4M 0.01% 981
2018
Q2
$124M Sell
7,962,456
-587,121
-7% -$8.88M 0.01% 893
2018
Q1
$129M Buy
8,549,577
+711,125
+9% +$10.8M 0.01% 865
2017
Q4
$113M Sell
7,838,452
-312,639
-4% -$4.3M 0.01% 959
2017
Q3
$123M Buy
8,151,091
+2,258,527
+38% +$29.9M 0.01% 871
2017
Q2
$59.3M Buy
5,892,564
+125,635
+2% +$1.01M 0.01% 1256
2017
Q1
$41.1M Buy
5,766,929
+50,982
+0.9% +$322K ﹤0.01% 1445
2016
Q4
$28.4M Buy
5,715,947
+622,349
+12% +$4.31M ﹤0.01% 1640
2016
Q3
$37.7M Buy
5,093,598
+612,982
+14% +$4.14M ﹤0.01% 1366
2016
Q2
$24.5M Buy
4,480,616
+661,186
+17% +$4.62M ﹤0.01% 1609
2016
Q1
$32.3M Sell
3,819,430
-1,337,428
-26% -$9.47M ﹤0.01% 1403
2015
Q4
$50M Buy
5,156,858
+1,769,519
+52% +$15.9M 0.01% 1178
2015
Q3
$47.4M Buy
3,387,339
+110,300
+3% +$1.73M 0.01% 1207
2015
Q2
$46.4M Buy
3,277,039
+845,810
+35% +$10.2M 0.01% 1319
2015
Q1
$26.5M Buy
2,431,229
+296,438
+14% +$2.61M ﹤0.01% 1644
2014
Q4
$17.8M Buy
2,134,791
+2,104,843
+7,028% +$14.4M ﹤0.01% 1885
2014
Q3
$179K Buy
29,948
+1,100
+4% +$5.76K ﹤0.01% 3489
2014
Q2
$97K Sell
28,848
-403,608
-93% -$947K ﹤0.01% 3471
2014
Q1
$894K Buy
432,456
+4,718
+1% +$11.8K ﹤0.01% 3271
2013
Q4
$1M Sell
427,738
-864
-0.2% -$1.9K ﹤0.01% 3254
2013
Q3
$992K Sell
428,602
-1,087
-0.3% -$2.73K ﹤0.01% 3250
2013
Q2
$1M Buy
+429,689
New +$1.32M ﹤0.01% 3187

Other funds holding FOLD

State Street's FOLD Position: Q1 2026 in Review

State Street reduced its Amicus Therapeutics (FOLD) stake by 13% in Q1 2026, selling an estimated $27.8M and leaving 12,893,897 shares worth $186M. The position accounts for 0.01% of the portfolio, ranked #978.

State Street first reported a position in FOLD in Q2 2013 and has held it in 52 quarters since. The position peaked at $211M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • State Street held 12,893,897 shares of Amicus Therapeutics worth $186M as of Q1 2026.
  • State Street sold 1,939,417 Amicus Therapeutics shares in Q1 2026, an estimated $27.8M.
  • Amicus Therapeutics made up 0.01% of State Street's portfolio in Q1 2026, its #978 holding.
  • State Street first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • State Street's Amicus Therapeutics position peaked at $211M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.